M42, Cleveland Clinic Abu Dhabi, Gunma University in Japan to drive innovation in heavy ion therapy
This collaboration, which took place during M42 and Cleveland Clinic Abu Dhabi's recent delegation visit to Japan, will see the three entities exchange knowledge, expertise and research to deepen scientific understanding and broaden the clinical applications of heavy ion therapy.
The collaboration builds on M42 and Cleveland Clinic Abu Dhabi's recent partnership with Toshiba Energy Systems & Solutions Corporation (Toshiba ESS) to establish the region's first heavy ion therapy facility in Abu Dhabi. This initiative will introduce one of the world's most innovative cancer treatment technologies to the Middle East, positioning Abu Dhabi as a centre of excellence in oncology and precision medicine.
With no heavy ion therapy centre within a five-hour flight of the UAE, the upcoming facility—strategically located on the Cleveland Clinic Abu Dhabi campus, adjacent to the Fatima bint Mubarak Centre, the region's first-of-its-kind comprehensive cancer centre—will enhance access to this treatment for patients across the Middle East.
Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'At Cleveland Clinic Abu Dhabi, our vision is to bring the most advanced, evidence-based treatments to our patients, and this partnership with Gunma University exemplifies that commitment. By combining our clinical expertise with Gunma's decades of leadership in heavy ion therapy, we are not only advancing scientific knowledge but also laying the groundwork for a new era of cancer care in the region."
President Ishizaki Yasuki at Gunma University, commented, 'Gunma University has long been committed to advancing the science of heavy ion therapy through rigorous research and clinical innovation."
He added, "Partnering with M42 will enable us to expand the reach of this transformative therapy, fostering international collaboration and ensuring that more patients worldwide benefit from the latest advancements in cancer treatment.'
Gunma University has been at the forefront of radiation oncology and nuclear medicine in Japan for decades. The Gunma University Heavy Ion Medical Centre (GHMC), established in 2005, has been instrumental in refining heavy ion radiotherapy by integrating radiation biology, clinical studies, and cutting-edge treatment technologies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
36 minutes ago
- Gulf Today
Aunt's heroic donation saves nephew as UAE doctors perform youngest infant liver transplant
A five-month old 4.4-kilogramme Emirati boy, stricken with a rare unpreventable recessive X disorder, and the youngest recipient of a donated liver in the UAE, courtesy of his 37-year-old paternal aunt, shall now be on lifelong monitoring and treatment. Fifth child Ahmed Al Yassi is recuperating at the Burjeel Medical City-Paediatric Intensive Care Unit (BMC-PICU) since his April 4, 2025 12-hour ultra-delicate transplantation. His giant strength, and his family's and the medical team's indefatigability, serve as an inspiring testimony for the August 13 'World Organ Donation Day." The WODD 2025 theme is 'Answering the Call,' for the continuous correct information dissemination on the necessity to grant one's organ/s to save lives. In the UAE, since 2017, is the Ministry of Health and Prevention-spearheaded National Programme for Donation and Transplantation of Human Organs and Tissues-Hayat Programme. According to a press statement, quoting undersecretary, Dr. Mohammed Salim Al Olama, it has been boosted with advanced digital solutions and artificial intelligence that guarantees transparency and efficiency at every stage of organ donation and transplantation process. Its website as of 4:30 p.m. of August 13 had '37,298 registered donors.' From a press statement quoting Department of Health-Abu Dhabi undersecretary Dr. Noura Khamis Al Ghaithi, 1,380 transplantations, through the Hayat Programme, were carried out from 2017 to 2024. The 2024 were at 290: seven heart, 142 kidney, 117 liver, 22 lung, and two pancreas. Over at BMC, elated was Ahmed's father Yahya: 'My baby's recovery is nothing short of a miracle. We were once a family living in fear of losing another child due to a liver problem. I hope our story inspires others to come forward, to learn more, and consider becoming donors. You never know whose life might change.' Abdominal Transplant and Hepato-Pancreatic Biliary surgeon Dr. Johns Shaji Mathew confirmed that Ahmed shall receive 'lifetime monitoring and therapy that includes immunosuppressive medications to prevent organ rejection, while the transplant on Ahmed has resolved the liver-related complications.' 'Ahmed will be regularly supervised by liver and genetics specialists for ongoing evaluation,' added Mathew, among the multi-disciplinary team members, led by Burjeel Abdominal Multi-Organ Transplant Programme-Transplant Surgery director Dr. Gourab Sen. The other on-case Transplant Team were Anaesthesia Division chairperson Dr. Ramamurthy Baskaran and specialists Dr. George Jacob and Dr. Anshu S., and Paediatric Intensive Care Unit (PICU) consultant Dr. Kesava Ramakrishnan. Their advice: 'urgent transplantation.' Ahmed's health debilitated due to the rise of his liver enzymes immediately birth. His diagnostics demonstrated that he is afflicted with ATP6AP1-Congenital Disorder of Glycosylation (ATP6AP1-CDG). Instrumental were the 'family's conviction' and the bravery-cum-volunteerism of mother-of-five Haifaa, Yahya's sister-in-law, who passed all compatibility tests. She and Ahmed are A+ blood type. Mathew said: 'The family's conviction came from the fact that without a transplant, Ahmed's survival chances were extremely low. They already experienced the loss of an older son to similar complications, which made them determined not to lose another.' 'The doctors gave us new hope. My sister-in-law gave us life again,' said Yahya. The USA-headquartered public-private-supported Frontiers in Congenital Disorders of Glycosylation (FCDG) portal notes that ATP6AP1-CDG generally affects males at one every one million. Ahmed has so far become the 31st survivor. There are 30 in other countries. The oldest patient is age 67. ATP6AP1-CDG 'age onset' range from the mother's pregnancy to age two, notes the Orphanet Knowledge on Rare Diseases and Orphan Drugs. From the FCDG, patients 'may have variable degree of liver dysfunction and immunodeficiency with recurrent infections.' Impaired-ness include developmental delays; abnormal body movement; gastrointestinal, urinary and genital problems; congenital heart defects and blood syndromes. So far, the solution is 'liver transplantation which has been successful in patients with severe liver failure.' Mathew said decreased transmission would only be via 'genetic screening and pre-marital genetic counselling to identify carriers and inform reproductive decisions for families with a known history.' Ahmed's family history has 'his grandfather passed on in 2010 due to a liver disease.' From the BMC Transplant Team that encourages a well-informed community on organ donation and transplantation: 'Ahmed's survival underscores the transformative power of organ donation and the advanced capabilities we now have in the UAE to perform complex, high-stakes surgeries for even the tiniest patients. Liver transplantation is not just surgical procedure; it is a second chance at life for those with no other options.'
The National
36 minutes ago
- The National
UAE telecoms authority begins public consultation for satellite reseller regulations
In what could be a watershed moment for satellite service re-sellers in the UAE, the country's telecoms regulator has announced that it was taking public input as it creates a licence framework. On its website, the UAE Telecommunications and Digital Government Regulatory Authority emphasised it wanted feedback for regulations to "regularise the current resale of satellite services". Once the TDRA finalises specifics for what it describes as a "category B" licence, the door would be opened for many businesses and entities to sell connectivity devices and services – paving the way for resellers of low-earth-orbit satellite internet communications devices such as Starlink. Under current regulations, only certain UAE entities with the current telecoms licence are permitted to provide these services. During the public consultation, the TDRA is seeking to "take relevant input provided by the stakeholders into consideration when drafting its regulation", according to the consultation form on the authority's website. According to SpaceX, operator of Starlink, the service is "pending regulatory approval" in the UAE. A document posted this year to the TDRA's website showed that Starlink was granted a regulatory licence in 2024 that will last about 10 years for 'maritime satellite internet services'. In the Middle East, Starlink is available in Qatar, Yemen, Oman, Bahrain, Jordan and Israel. Jimmy Grewal, executive director Dubai-based marine electronics company Elcome International, said he was excited about the the opportunities presented during the public comment period. "The TDRA's open consultation is a welcome step that brings clarity to a fast-moving market and will accelerate the safe rollout of next-generation satellite connectivity across the UAE," he said. Mr Grewal said a detailed framework for resellers like Elcome will strengthen options, resilience and productivity for government, maritime, aviation and offshore energy sector workers seeking internet and communications connectivity. He said he was also prepared for the possibility of the regulations opening the door for Starlink access in the UAE. "As one of the first and largest Starlink resellers in the world, Elcome is keen to bring the benefits of Starlink to our home market once the new regulatory framework is in place," Mr Grewal said. According to the TDRA's feedback form posted on its website, relevant entities are being asked about ideal licence durations, satellite reseller fees and overall reactions to draft legislation. The regulatory body is accepting public consultation until September 25.
Arabian Business
an hour ago
- Arabian Business
Salik declares 100% payout as H1 earnings hit $210m following new gates and variable pricing
Dubai toll gate operator Salik has reported a sharp increase in first-half earnings for 2025, driven by new toll gates, the introduction of variable pricing, and resilient traffic volumes. Total revenue for the first six months of 2025 rose 39.5 per cent year-on-year to AED1.53bn ($415.8m), with Q2 revenue up 45.6 per cent to AED775.7m ($210.9m). EBITDA climbed 44.2 per cent in H1 to AED1.07bn ($290m), maintaining a healthy margin of 69.7 per cent. Salik results Net profit for H1 jumped 41.5 per cent to AED770.9m ($210.1m), prompting the board to recommend a cash dividend equal to 100 per cent of first-half profit — 10.278 fils per share. Salik's core tolling business handled 424.2m total trips in H1 2025, up 39.6 per cent from a year earlier, with 213.4m trips recorded in Q2 alone. Total chargeable trips rose to 160.4m in Q2, up 1.6 per cent from Q1, bolstered by a 46.7 per cent surge in peak-period trips following the November 2024 addition of two new gates. Toll usage fees for H1 rose 42.3 per cent to AED1.36bn ($370.2m), with Q2 toll fees up 49.4 per cent year-on-year to AED691.3m ($187.9m) — the first full quarter under the new variable pricing model introduced at the end of January 2025. Revenue from fines increased 15.7 per cent in H1 to AED134.3m ($36.6m), while tag activation fees rose 16.2 per cent to AED22.9m ($6.2m). Non-toll income reached AED8.7m ($2.37m) in H1, supported by partnerships with Emaar Malls and Parkonic for parking payment solutions, now active in 73 locations. Salik also continues to expand its cooperation with Liva Group to streamline vehicle insurance renewals. Mattar Al Tayer, Chairman of the Board of Directors of Salik, said:'Salik's strong performance in the first half of 2025 underscores the strength of its resilient business model and high operational efficiency. 'During this period, the Company achieved a 39.5 per cent year-on-year increase in total revenue, further solidifying its robust financial position. 'This performance reaffirms our continued commitment to delivering long-term value for shareholders while supporting Dubai's vision of becoming a global leader in smart and sustainable mobility. 'In view of the strong first half results and our dedication to our shareholders, the Board of Directors have recommended a cash dividend of AED 770.9 million, equivalent to 10.278 fils per share, representing 100 per cent of H1 2025 profit. 'We continue to benefit from the Emirate's economic momentum, bolstered by sustained growth in tourism, real estate, and infrastructure spending. Building on this, and with continued progress across both our core tolling operations and ongoing success in expanding our ancillary revenue streams, we are pleased to be upgrading our full year 2025 guidance, with revenue expected to increase 34-36 percent compared to 2024, up from 28-29 per cent previously, and with EBITDA margins expectations in the range of 68.5-69.5 per cent. 'Our new guidance underscores our confidence in Salik's outlook and future growth potential, particularly given our commitment to strengthening our non-core offering and exploring new opportunities within ancillary revenues.' Ibrahim Sultan Al Haddad, CEO of Salik, said: 'We are pleased to report another solid quarter of performance, with a strong c.40% YoY growth across all key financial metrics including revenue, EBITDA and net profit growth. 'Our results reflect the ongoing strength of our tolling business and the growing contribution of our non-tolling initiatives, including our digital partnerships in providing mobility payment solutions which continue to gain traction among users.'
